Moreover, the inhibition of MAO-B is already a treatment target for Parkinson’s disease and major depression; those drugs have also been evaluated for their potential in the treatment of Alzheimer’s disease, Lewy Body diseases with dementia, amyotrophic lateral sclerosis, and Huntington’s disease [37]. The gene discussed is MAOB; the disease is Parkinson disease.